Forge Biologics, a manufacturer of genetic medicines, will collaborate with Labcorp, a global life sciences company, on gene therapy development and manufacturing.
Under the alliance, gene therapy clients will have access to manufacturing capabilities, drug development services, and coordinated scientific expertise, creating greater accessibility to services for adeno-associated virus (AAV) mediated gene therapy programs.
Working jointly, Labcorp and Forge aim to accelerate clinical timelines, reduce analytical development constraints, and mitigate potential regulatory challenges related to manufacturing and development processes.
